The Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack and non-fatal stroke, in adults with type 2 diabetes who are at high risk for those events. Eli Lilly announced the approval Friday morning.
Mounjaro, the brand name for tirzepatide, was already approved as an addition to diet and exercise to improve blood sugar in adults and children aged 10 and older with type 2 diabetes. Lilly describes it as the most-prescribed branded type 2 diabetes medication for adults in the United States. The new indication adds heart protection to the label of a drug many Americans already inject weekly.
For anyone currently taking Mounjaro, nothing changes today. No dose changes, no new prescription, no action required. What changes is the conversation, because a cardiovascular indication on a label affects how physicians choose between diabetes drugs and how insurers decide what to cover.
The Trial Compared Two Drugs Against Each Other Rather Than Against a Placebo
The approval rests on SURPASS-CVOT, and the trial design is unusual enough to explain before the numbers.
Most cardiovascular outcomes trials test a drug against a placebo. This one tested Mounjaro against Trulicity, another Lilly drug that already has an approved cardiovascular indication. Lilly describes it as the first cardiovascular outcomes trial comparing two incretin medicines head-to-head.
The trial enrolled 13,299 participants across 640 sites in 30 countries, randomized 1:1 to receive Mounjaro at 15 milligrams or the maximum tolerated dose, or Trulicity at 1.5 milligrams, injected subcutaneously once weekly. Participants were adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Their mean age was 64, and 29 percent were women. Median follow-up was 210.1 weeks, about four years, and the trial itself lasted roughly five years.
Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said the company chose a demanding comparison. "We set a higher bar by testing Mounjaro against a GLP-1 medicine," he said, referring to a drug with proven cardiovascular benefit.
Non-Inferior Is the Word Carrying the Weight Here
The trial met its primary objective, and the precise meaning of that is worth stating plainly rather than leaving to inference.
Over a median of four years, the combined rate of cardiovascular death, heart attack or stroke was 12.2 percent among participants taking tirzepatide and 13.1 percent among those taking dulaglutide, as reported by TCTMD when the full results were published in the New England Journal of Medicine. That difference met the statistical threshold for non-inferiority but not for superiority. The estimated hazard ratio was 0.92, with a 95.3 percent confidence interval ranging from 0.83 to 1.01, and Lilly states explicitly that superiority over dulaglutide was not established.
In plain terms, Mounjaro was shown to work about as well as a drug that already protects the heart. It was not shown to work better.
That is still a meaningful result. Because Trulicity's own cardiovascular benefit was established against placebo in an earlier trial, matching it is evidence that Mounjaro carries a genuine cardiovascular benefit rather than merely an absence of harm. Stephen Nicholls, the lead investigator, told TCTMD that the finding "validates the cardiovascular benefit of tirzepatide" and gives patients greater choice.
Some secondary measures numerically favored tirzepatide, including an expanded endpoint that added coronary revascularization and a lower rate of all-cause death that appeared driven by non-cardiovascular deaths. Because the trial was designed to test non-inferiority on a single primary endpoint, those secondary findings are best read as supportive rather than as established benefits in their own right.
Tirzepatide did produce larger metabolic changes. Participants taking it lost more weight than those on dulaglutide, 11.6 percent versus 4.5 percent from baseline, and had larger reductions in glycated hemoglobin, 1.66 percentage points versus 0.88. Those differences did not translate into a significant difference in cardiovascular events.
Mounjaro Is Not Zepbound, and the Distinction Affects Coverage
This is the point most likely to be misread, and it matters financially.
Tirzepatide is sold under two names. Mounjaro is approved for type 2 diabetes and now for cardiovascular risk reduction. Zepbound is the same molecule approved for chronic weight management and obstructive sleep apnea. The FDA approves drugs by indication, so the name on the box reflects the approved use rather than what the molecule does.
Today's approval does not add a weight-loss indication to Mounjaro. It does not change Zepbound's label. Anyone hoping this makes Mounjaro easier to get covered for weight loss should not expect that.
Where it may matter is for patients with type 2 diabetes and heart disease, since insurers frequently tie coverage decisions to approved indications. Patients facing a denial can ask their prescriber about prior authorization, appeals, and manufacturer savings programs, though prior authorization approval is not the same as a paid claim.
The reach is potentially wide. Research cited by Lilly estimates that as many as one in three U.S. adults with type 2 diabetes have undetected cardiovascular disease. Worth noting for precision: all trial participants had established atherosclerotic disease, whereas the approved indication covers a broader group described as high risk.
Side Effects and One Interaction Worth Flagging
The safety profile did not change with this approval, and the prescribing information remains the authoritative source.
Mounjaro carries a boxed warning about the risk of thyroid tumors, including thyroid cancer. It should not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. The most common side effects are gastrointestinal, generally mild to moderate, and occur during dose increases. In the trial, adverse events led 13.2 percent of tirzepatide participants to stop treatment, compared with 10.1 percent on dulaglutide, a gap driven largely by gastrointestinal effects.
Serious reported risks include pancreatitis, low blood sugar when combined with insulin or a sulfonylurea, gallbladder problems, dehydration leading to kidney problems, vision changes, and an increased chance of food entering the lungs during anesthesia. Anyone scheduled for surgery or a procedure with sedation should tell the whole care team they take it.
One interaction gets overlooked. Oral birth control pills may not work as well while a patient is using Mounjaro. Lilly advises considering another contraceptive method for four weeks after starting and for four weeks after each dose increase.
Nobody should start, stop, or change a diabetes medication based on a label update. Data from the trial has already been added to Mounjaro's product information in the European Union, and regulatory submissions are under review in other markets.
Key Questions Answered
What exactly did the FDA approve? Mounjaro can now be prescribed to lower the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with type 2 diabetes who are at high risk for those events.
Does this mean Mounjaro beat the drug it was tested against? No. It met the standard for non-inferiority to Trulicity but not for superiority. Rates were 12.2 percent versus 13.1 percent over about four years, a difference that was not statistically significant.
Should I ask my doctor to switch me to Mounjaro? That is a decision for you and your clinician. The trial supports Mounjaro as a reasonable option for people with type 2 diabetes and heart disease, not as proof it is better than the alternatives.
Does this approval cover weight loss? No. Mounjaro remains approved for type 2 diabetes and now cardiovascular risk reduction. The same molecule is sold as Zepbound for chronic weight management and obstructive sleep apnea, and that label is unchanged.
Who was actually studied? Adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The approved indication is somewhat broader, covering adults with type 2 diabetes at high risk of cardiovascular events.
What are the main safety concerns? A boxed warning about thyroid tumors, common gastrointestinal side effects during dose escalation, and reported risks including pancreatitis, gallbladder problems, low blood sugar with certain other diabetes medicines, and food entering the lungs during anesthesia.
Is there a drug interaction I should know about? Oral contraceptives may be less effective. Lilly advises using another contraceptive method for four weeks after starting Mounjaro and for four weeks after each dose increase.
